How to Value an Allergy and Immunology Practice in 2026

Allergy and immunology practices are among the most attractive physician practice acquisitions in healthcare M&A, and most allergists don't fully appreciate why. The answer comes down to one word: recurrence. A patient starting subcutaneous immunotherapy (allergy shots) commits to weekly or biweekly office visits for 3-5 years. That's not recurring revenue in the SaaS sense — it's even better, because patients are medically motivated to continue, and stopping mid-course means starting over.

I've worked on allergy practice transactions ranging from solo practitioners to multi-provider groups, and the valuation dynamics are distinct from general practice medicine. Understanding what drives value in this specialty requires looking at the revenue composition, not just the top-line numbers.

The Multiples: Where Allergy Practices Trade

Allergy and immunology practices trade at 4-8x EBITDA, placing them in the upper tier of physician practice valuations. For context, primary care trades at 4-7x, general dermatology at 5-8x, and cardiology at 6-10x. The allergy range is wide because the revenue mix varies enormously between practices — and that mix is what determines where you fall.

Solo allergists with heavy owner dependency and limited ancillary services sit at the lower end (4-5x). Multi-provider groups with robust immunotherapy programs, biologics administration, and in-office testing capabilities trade at 6-8x. The premium reflects both the quality of the revenue streams and the scalability of the practice model.

For smaller practices (under $1M revenue), SDE may be the more appropriate metric, with multiples ranging from 2-3.5x SDE. The shift to EBITDA-based valuation happens once the practice has associate providers and the selling physician's compensation can be normalized.

Allergy Shot Revenue: The Golden Goose

Subcutaneous immunotherapy (SCIT) — allergy shots — is the single most valuable revenue stream in an allergy practice, and it's what makes this specialty uniquely attractive to acquirers.

Here's why the math is so compelling. A patient on allergy shots visits the office 1-2 times per week during the buildup phase (typically 6-12 months), then monthly during the maintenance phase (3-5 years). Each visit generates $25-50 in injection administration fees plus the allergen extract itself. A single immunotherapy patient generates $3,000-$8,000 in total revenue over the course of treatment. Multiply that by 200-400 active immunotherapy patients in a mid-sized practice, and you have a $600K-$3.2M annual revenue stream that is extraordinarily sticky.

Buyers value immunotherapy revenue at a premium because of three characteristics that most medical revenue lacks. First, it's predictable— patients on active immunotherapy schedules show up consistently because missing appointments disrupts their treatment. Second, it's long-duration— a 3-5 year treatment course means the revenue stream doesn't evaporate when the selling physician departs. Third, it's provider-independent — allergy shots are administered by nurses or medical assistants under physician supervision. The patient relationship may be with the allergist, but the treatment execution doesn't require them to be in the room.

The key metric buyers analyze is active immunotherapy patients as a percentage of total active patients. Practices where 25-40% of active patients are on immunotherapy protocols are at the top of the valuation range. Below 15%, and the practice looks more like a general consult-and-refer model, which is less defensible and less valuable.

Biologics Administration: The Growth Story

The biologics revolution has transformed allergy practice economics. Drugs like Dupixent (dupilumab), Xolair (omalizumab), Nucala (mepolizumab), and Fasenra (benralizumab) are administered in-office and generate substantial revenue per patient per year.

A practice administering biologics benefits from both the drug reimbursement and the administration fee. Depending on the biologic and payer, total reimbursement per patient can range from $15,000-$40,000 annually. Even after drug acquisition costs, the margin on biologics administration is meaningful — and the patient commitment mirrors immunotherapy: these are ongoing treatments that patients continue indefinitely.

Buyers are particularly excited about biologics-heavy practices because the pipeline of new allergy and immunology biologics is robust. Tezspire, Adbry, and several others in late-stage trials suggest the addressable patient population will only grow. A practice with established biologics infrastructure — buy-and-bill capabilities, prior authorization expertise, trained nursing staff — is positioned to capture that growth without significant additional investment.

The risk buyers watch for: payer mix on biologics patients. If your biologics revenue is heavily concentrated in one payer, a single formulary change or reimbursement cut can materially impact revenue. Diversified payer mix across your biologics book is a meaningful value protector.

Testing Revenue and In-Office Ancillaries

Allergy testing — skin prick testing, intradermal testing, patch testing, and component testing — is another high-margin, in-office revenue stream that buyers value. A comprehensive testing panel generates $400-$1,200 per patient, performed by a trained technician with physician interpretation.

Spirometry and pulmonary function testing add another dimension, particularly for practices that manage asthma alongside allergies. FeNO (fractional exhaled nitric oxide) testing has become standard of care for asthma management and generates $50-100 per test at strong margins.

The practices that maximize testing revenue have systematized their diagnostic protocols. Every new patient gets a comprehensive workup. Existing patients get periodic retesting to guide treatment decisions. This isn't upcoding or unnecessary testing — it's thorough diagnostic medicine that happens to generate strong ancillary revenue. Buyers look at testing revenue per new patient encounter as a metric for how well the practice captures its diagnostic opportunity.

What Moves the Multiple Higher

Provider depth. A multi-allergist practice with 2-3 physicians and 1-2 APPs (nurse practitioners or physician assistants) trades at a significant premium to a solo practice. The owner dependency risk in a solo allergy practice is real — if the allergist leaves and patients scatter, the immunotherapy revenue stream that justifies the premium multiple evaporates.

Payor diversification. Practices with balanced commercial, Medicare, and Medicare Advantage payer mix are more resilient to reimbursement changes. Heavy Medicare concentration (above 40%) exposes the practice to CMS rate cuts, while heavy commercial concentration in one or two payers creates contract renegotiation risk.

Sublingual immunotherapy (SLIT) programs. Practices that offer both subcutaneous and sublingual immunotherapy capture a broader patient population. SLIT patients don't generate office visit revenue (they take drops or tablets at home), but SLIT protocol fees and ongoing monitoring visits add incremental revenue and demonstrate clinical sophistication.

Referral network strength. Allergy practices that receive consistent referrals from a broad base of primary care physicians have more defensible patient flow than those relying on direct-to-consumer marketing. A documented referral network with 20+ referring physicians is a tangible asset in the buyer's eyes.

What Compresses the Multiple

Consult-heavy, treatment-light model. If your practice sees patients for initial evaluations and allergy testing but sends them to another provider or home with OTC medications rather than building an immunotherapy or biologics book, you're leaving the most valuable revenue streams on the table. Buyers will apply a lower multiple to a practice that generates most of its revenue from E&M visits rather than from ongoing treatment administration.

Aging patient panel with low new patient volume. A practice with 3,000 active patients but only 15 new patients per month is slowly depleting its base. Buyers want to see a healthy new patient acquisition rate (30-50+/month for a mid-sized practice) that replenishes natural attrition and feeds the immunotherapy funnel.

No EMR or outdated systems. Practices still on paper charts or legacy EMR systems face integration costs and operational disruption post-acquisition. Modern EMR with integrated scheduling, billing, and immunotherapy tracking is a baseline expectation.

Regulatory exposure. Allergy extract preparation and storage must comply with FDA and state pharmacy board requirements. Practices with compliance issues or inadequate extract handling documentation create diligence red flags that slow or kill deals.

Platform vs. Bolt-On: The Buyer Landscape

The allergy practice acquisition market has two distinct buyer types, and the valuation implications are significant.

Hospital systems and large medical groups acquire allergy practices to fill specialty gaps in their networks. They typically pay 4-6x EBITDA, apply their own overhead structure (which may or may not improve margins), and integrate the practice into their referral ecosystem. The selling allergist usually becomes an employed physician with a 2-3 year employment agreement.

PE-backed allergy and ENT platforms are increasingly active, recognizing the same recurring revenue dynamics that make the specialty attractive. Platform multiples run 6-8x for anchor acquisitions, with bolt-ons at 4-5x. If your practice has platform scale ($2M+ EBITDA, multiple providers, multiple locations), the PE route can yield significantly higher valuations.

The Bottom Line

Allergy and immunology practices command premium valuations in healthcare M&A because of their uniquely recurring revenue model. A patient starting allergy shots today represents 3-5 years of predictable, provider-independent revenue — and that's before accounting for biologics administration, testing, and ongoing management. The practices that trade at the top of the 4-8x EBITDA range are the ones that have built deep immunotherapy and biologics programs, developed provider depth beyond a single allergist, and created systematic diagnostic protocols that maximize in-office ancillary revenue. If you own an allergy practice and are considering an exit, the size and composition of your active immunotherapy book is the single most important factor in your valuation.